Syndrome X

Past, Present, and Future
  • Gerald M. Reaven
Part of the Contemporary Biomedicine book series (CB, volume 15)


In 1988 I suggested that a defect in the ability of insulin to stimulate glucose disposal played a major role in the pathogenesis and clinical course of what are often referred to as diseases of Western civilization (1). It had been apparent for some time that resistance to insulin-mediated glucose disposal was a common finding in patients with noninsulin-dependent diabetes mellitus (NIDDM), and that fasting hyperglycemia supervened in such individuals when they no longer were able to sustain the degree of compensatory hyperinsulinemia necessary to overcome the defect in cellular insulin action (2–5). However, what was not as well appreciated was the fact that insulin-resistant subjects able to sustain the degree of compensatory hyperinsulinemia necessary to maintain near-normal glucose homeostasis were at risk of developing a cluster of additional abnormalities, including some impairment of glucose tolerance, a high plasma triglyceride (TG) and a low high-density lipoprotein (HDL) cholesterol concentration, and hypertension (1). This cluster of related abnormalities, all of which increase risk of coronary heart disorder (CHD), was designated as Syndrome X. Since that time, this formulation has received considerable support (6–8). Furthermore, the list of abnormalities associated with insulin resistance and compensatory hyperinsulinemia has grown to include higher serum uric acid concentrations (9),smaller and denser low-density lipoprotein (LDL) particles (10),accentuation of postprandial lipemia (11), and increased concentration of plasminogen activator inhibitor (PAI)-1 (12).


Insulin Resistance Postprandial Lipemia High Density Lipoprotein Cholesterol Concentration Plasma Insulin Response Compensatory Hyperinsulinemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1495–1607.Google Scholar
  2. 2.
    Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 1975; 55: 454–461.PubMedGoogle Scholar
  3. 3.
    DeFronzo R, Deibert D, Hendler R, Felig P, Soman V. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest 1979; 63: 939–946.PubMedGoogle Scholar
  4. 4.
    Kolterman OB, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM. Recpetor and post-receptor defects contribute to the insulin resistance in noninsulin dependent diabetes mellitus. J Clin Invest 1981; 68: 957–969.PubMedGoogle Scholar
  5. 5.
    Reaven GM. Insulin resistance in noninsulin-dependent diabetes mellitus: does it exist and can it be measured? Am J Med 1983; 74: 3–17.PubMedGoogle Scholar
  6. 6.
    Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893–2898.PubMedGoogle Scholar
  7. 7.
    Landin K. Tengvory L, Smith U. Elevated firbonogen and plasminogen activator (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273–278.Google Scholar
  8. 8.
    Ferrannini E, Haffner SM, Mitchell BD, Stem MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 3: 416–422.Google Scholar
  9. 9.
    Facchini F, Chen Y-DI, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008–3011.PubMedGoogle Scholar
  10. 10.
    Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141–146.PubMedGoogle Scholar
  11. 11.
    Jeppesen J, Hollenbeck CB, Zhous M-Y, Coulston AM, Jones C, Chen Y-DI, Reaven GM. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arteriosclerosis Thromb Vascular Biol 1995; 15: 320–324.Google Scholar
  12. 12.
    Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. Arteriosclerosis Thromb 1993; 13: 1865–1873.Google Scholar
  13. 13.
    Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 236: 13–22.Google Scholar
  14. 14.
    Kemp HG. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol 1973; 32: 375, 376.Google Scholar
  15. 15.
    Dean JD, Jones CJH, Hutchison SJ, Peters JR, Henderson AH. Hyperinsulinaemia and microvascular angina (“syndrome X”). Lancet 1991; 337: 456, 457.Google Scholar
  16. 16.
    Fuh MM-T, Jeng C-Y, Young MM-S, Sheu WH-H, Chen Y-DI, Reaven GM. Insulin resistance, glucose intolerance, and hyperinsulinaemia in patients with microvascular angina. Metabolism 1993; 42: 1090–1092.PubMedGoogle Scholar
  17. 17.
    Botker HE, Moller N, Ovesen P, Mengel A, Schmitz O, Orskov H, Bagger JP. Insulin resistance in microvascular angina (syndrome X). Lancet 1993; 342; 136–140.PubMedGoogle Scholar
  18. 18.
    Vestergaard H, Skett P, Steffensen R, Wroblewski H, Pedersen O, Kastrup J. Insulin-resistant glucose metabolism in patients with microvascular angina-Syndrome X. Metabolism 1995; 44: 876–882.PubMedGoogle Scholar
  19. 19.
    Steiner G. Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients: a double-blind study with gemfribrozil with implications for atherosclerosis. Diabetes Care 1991; 14: 1077–1081.PubMedGoogle Scholar
  20. 20.
    Olefsky JM, Reaven GM, Farquhar JW. Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism. J Clin Invest 1974; 53: 64–76.PubMedGoogle Scholar
  21. 21.
    Kissebah AH, Vydelingum N, Murrary R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254–260.PubMedGoogle Scholar
  22. 22.
    Peiris AN, Struve MF, Mueller RA, Lee MB, Kissebah AH. Glucose metabolism in obesity: influence on body fat distribution. J Clin Endocrinol Metab 1988; 67: 760–767.PubMedGoogle Scholar
  23. 23.
    Landin K, Krotkiewski M, Smith U. Importance of obesity for the metabolic abnormalities associated with an abdominal fat distribution. Metabolism 1989; 38: 572–576.PubMedGoogle Scholar
  24. 24.
    Shen D-C, Shieh S-M, Fuh M-T, Chen Y-DI. Comparison of the effects of differences in ratio of waist to hip girth and body mass index on carbohydrate metabolism in Chinese females. Horm Metab Res 1990; 22: 533–536.PubMedGoogle Scholar
  25. 25.
    Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. New Engl J Med 1989; 321: 337–343.PubMedGoogle Scholar
  26. 26.
    Laws A, Stefanick ML, Reaven GM. Insulin resistance and hypertriglyceridemia in on diabetic relative of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 343–347.PubMedGoogle Scholar
  27. 27.
    Ho LT, Chang ZY, Wang JY, et al. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabetic Med 1989; 7: 31–34.Google Scholar
  28. 28.
    Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of Type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909–915.PubMedGoogle Scholar
  29. 29.
    Hollenbeck CB, Chen Y-DI, Reaven GM. A comparison of the relative effects of obesity and non-insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization. Diabetes 1984; 33: 622–626.PubMedGoogle Scholar
  30. 30.
    Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514–1520.PubMedGoogle Scholar
  31. 31.
    Modan M, Halkin G, Almog S et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. Hypertension 1985; 75: 809–817.Google Scholar
  32. 32.
    Nabulsi AA, Folsom AR, Heiss G, Weir SS, Chambless LE, Watson RL, Eckfeldt JH, for the Atherosclerosis Risk in Communities Study Investigators. Fasting hyperinsulinemia and cardiovascular disease risk factors in nondiabetic adults: stronger associations in lean versus obese subjects. Metabolism 1995; 44: 914–922.PubMedGoogle Scholar
  33. 33.
    Zavaroni I, Bonini L, Fantuzzi M, Dall’Aglio E, Passeri M, Reaven GM. Hyperinsulinaemia, obesity and syndrome X. J Intern Med 1994; 235: 51–56.PubMedGoogle Scholar
  34. 34.
    Rosenthal M, Haskell WL, Solomon R, Widstrom A, Reaven GM. Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. Diabetes 1983; 32: 408–411.PubMedGoogle Scholar
  35. 35.
    Hollenbeck CB, Haskell W, Rosenthal M, Reaven GM. Effect of habitual physical activity on regulation of insulin-stimulated glucose disposal in older males. J Am Geriatr Soc 1985; 33: 273–277.PubMedGoogle Scholar
  36. 36.
    Krotkiewski M, Mandroukas K, Sjostrom L, Sullivan L, Wetterqvist H, Bjornstorp P. Effects of long-term physical training on body fat, metabolism, and blood pressure in obesity. Metabolism 1979; 28: 650–658.PubMedGoogle Scholar
  37. 37.
    DeFronzo RA, Sherwin RS, Kraemer N. Effect of physical training on insulin action in obesity. Diabetes 1987; 1379–1385.Google Scholar
  38. 38.
    Rodnick KJ, Haskell WL, Swislocki ALM, Foley JE, Reaven GM. Improved insulin action in muscle, liver, and adipose tissue in physically trained human subjects. Am J Physiol 1987; 253: E489 - E495.PubMedGoogle Scholar
  39. 39.
    Schwarz RS. The independent effects of dietary weight loss and aerobic training on high density lipoproteins and apolipoprotein A-1 concentrations in obese men. Metabolism 1987; 36: 165–171.Google Scholar
  40. 40.
    Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985; 248: E286–291.PubMedGoogle Scholar
  41. 41.
    Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Brit Med J 1989; 298: 784–788.PubMedGoogle Scholar
  42. 42.
    Willett W, Hennekens CH, Catelli W, et al. Effects of cigarette smoking on fasting triglyceride, total cholesterol and high density lipoprotein cholesterol in women. Am Heart J 1983; 105: 417–421.PubMedGoogle Scholar
  43. 43.
    Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992; 231: 25–30.PubMedGoogle Scholar
  44. 44.
    Facchini F, Hollenbeck CB, Jeppesen J, Chen Y-DI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128–1130.PubMedGoogle Scholar
  45. 45.
    Zavaroni I, Bonini L, Gasparini P, Dall’Aglio E, Paseri M, Reaven GM. Cigarette smokers are relatively glucose intolerant, hyperinsulinemic and dyslipidemic. Am J Cardiol 1994; 73: 904, 905.Google Scholar
  46. 46.
    Eliasson B, Attvall S, Taskinen M-R, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. Arteriosclerosis Thromb 1994; 14: 1946–1950.Google Scholar
  47. 47.
    Hollenbeck CB, Chen N, Chen Y-DI, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 1984; 33: 460–463.PubMedGoogle Scholar
  48. 48.
    Austin MA. Plasma triglyceride and coronary heart disease. Arteriosclerosis Thromb 1991; 11: 2–14.Google Scholar
  49. 49.
    Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 1974; 23: 449–453.PubMedGoogle Scholar
  50. 50.
    Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967; 46: 1756–1767.PubMedGoogle Scholar
  51. 51.
    Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57: 551–560.PubMedGoogle Scholar
  52. 52.
    Jeng C-Y, Fuh MM-T, Sheu WH-H, Chen Y-DI, Reaven GM. Hormone and substrate modulation of plasma triglyceride concentration in primary hypertriglyceridaemia. Endocrinol Metab 1994; 1: 15–21.Google Scholar
  53. 53.
    Reaven GM. Insulin-stimulated glucose disposal in patients with Type I (IDDM) and Type II (NIDDM) diabetes mellitus. In: Comparison of Type I and Type II Diabetes. Vranic M, Hollenberg CH, Steiner G eds. New York: Plenum, pp. 129–136, 1985.Google Scholar
  54. 54.
    Reaven GM, Greenfield MS. Diabetic hypertriglyceridemia: evidence for three clinical syndromes. Diabetes 1981; 30: 66–75.PubMedGoogle Scholar
  55. 55.
    Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic man. Metabolism 1981; 30: 165–171.PubMedGoogle Scholar
  56. 56.
    Riccardi G, Genovese S, Saldalamacchia G, Patti L, Marotta G, Postiglione A, et al. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes. Atherosclerosis 1989; 75: 175–181.PubMedGoogle Scholar
  57. 57.
    Vuorinen-Markkola H, Yki-Järvinen H, Taskinen M-R. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in Type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993; 36: 161–169.PubMedGoogle Scholar
  58. 58.
    Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Järvinen H, Taskinen M-R. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 1995; 44: 589–596. 59.Google Scholar
  59. 59.
    Ahrens EH Jr, Hirsch J, Oette K, Farquhar JW, Stein Y. Carbohydrate-induced and fat-induced lipemia. Trans Assoc Am Phys 1961; 74: 134.PubMedGoogle Scholar
  60. 60.
    Farquhar JW, Frank A, Gross RC, Reaven. Glucose, insulin, and triglyceride responses to high and low carbohydrate diets in man. J Clin Invest 1966; 45: 1648–1656.Google Scholar
  61. 61.
    Coulston AM, Liu GC, Reaven GM. Plasma glucose, insulin and lipid responses to high-carbohydrate low-fat diets in normal humans. Metabolism 1983; 32: 52–56.PubMedGoogle Scholar
  62. 62.
    Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes 1992; 41: 1278–1285.PubMedGoogle Scholar
  63. 63.
    Kolterman OG, Greenfield M, Reaven GM, Saekow M, Olefsky JM. Effect of a high carbohydrate diet on insulin binding to adipocytes and on insulin action in vivo in man. Diabetes 1979; 28: 731–736.PubMedGoogle Scholar
  64. 64.
    Wilson DE, Hata A, Kwong LK, Lingam A, Shuhua J, Ridinger DN, Yeager C, Kaltenborn KC, Iverius PH, Lalouel JM. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes. J Clin Invest 1993; 92: 203–211.PubMedGoogle Scholar
  65. 65.
    Durrington PN, Newton RS, Weinstein DB, et al. Effects of insulin and glucose on very-lowdensity lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest 1982; 70: 63–73.PubMedGoogle Scholar
  66. 66.
    Patsch W, Franz S, Schonfeld G. Role of insulin in lipoprotein secretion by cultured hepatocytes. J Clin Invest 1983; 71: 1161–1174.PubMedGoogle Scholar
  67. 67.
    Swenson TL. The role of the cholesteryl ester transfer protein in lipoprotein metabolism. diabetes Metab Rev 1991; 7: 139–153.PubMedGoogle Scholar
  68. 68.
    Fidge N, Nestel P, Toshitsugu I, Reardon M, Billington T. Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism 1980; 29: 643–653.PubMedGoogle Scholar
  69. 69.
    Chen Y-DI, Sheu WH-H, Swislocki ALM, Reaven GM. High density lipoprotein turnover in patients with hypertension. Hypertension 1991; 17: 386–393.PubMedGoogle Scholar
  70. 70.
    Golay A, Zech L, Shi M-Z, Chiou Y-AM, Reaven GM, Chen Y-DI. High density lipoprotein (HDL) metabolism i noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 1987; 65: 512–518.PubMedGoogle Scholar
  71. 71.
    Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arteriosclerosis Thromb 1994; 14: 707–720.Google Scholar
  72. 72.
    Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473–485.PubMedGoogle Scholar
  73. 73.
    Chen Y-DI, Reaven GM. Intestinally-derived lipoproteins: metabolism and clinical significance. Diabetes/Metab Rev 1991; 7: 191–208.Google Scholar
  74. 74.
    Nestel PJ. Relationship between plasma triglycerides and removal of chylomicrons. J Clin Invest 1964; 43: 943–949.PubMedGoogle Scholar
  75. 75.
    Wilson DE, Chan I-F, Buchi KN, Horton SC. Postchallenge plasma lipoprotein retinoids: chylomicron remnants in engodenous hypertriglyceridemia. Metabolism 1985; 34: 551–558.PubMedGoogle Scholar
  76. 76.
    Chen Y-DI, Swami S, Skowronski R, Coulston AM, Reaven GM. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 76: 172–177.PubMedGoogle Scholar
  77. 77.
    Jeppesen J, Hollenbeck CB, Zhous M-Y, Coulston AM, Jones C, Chen Y-DI, Reaven GM. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arteriosclerosis Thromb Vascular Biol 1995; 15: 320–324.Google Scholar
  78. 78.
    Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WS, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917–1921.PubMedGoogle Scholar
  79. 79.
    Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495–506.PubMedGoogle Scholar
  80. 80.
    Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141–146.PubMedGoogle Scholar
  81. 81.
    Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263–268.Google Scholar
  82. 82.
    Juhan-Vague I, Alessel MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457–462.PubMedGoogle Scholar
  83. 83.
    Juhan-Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. Arteriosclerosis Thromb 1993; 13: 1865–1873.Google Scholar
  84. 84.
    Potter Van Loon BJ, Kluft JC, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism 1993; 42: 945–949.Google Scholar
  85. 85.
    Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. New Engl J Med 1987; 317: 350–357.PubMedGoogle Scholar
  86. 86.
    Shen D-C, Shieh S-M, Fuh M, Wu D-A, Chen Y-DI, Reaven GM. Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580–583.PubMedGoogle Scholar
  87. 87.
    Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167–174.PubMedGoogle Scholar
  88. 88.
    Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y, Heynen G. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589–596.PubMedGoogle Scholar
  89. 89.
    Facchini F, Chen Y-DI, Clinkingbeard C, Jeepesen J, Reaven GM. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertension 1992; 5: 694–699.Google Scholar
  90. 90.
    Hwang I-S, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512–516.PubMedGoogle Scholar
  91. 91.
    Reaven GM, Ho H, Hoffman BB. Attenuation of fructose-induced hypertension in rats by exercise training. Hypertension 1988; 12: 129–132.PubMedGoogle Scholar
  92. 92.
    Reaven GM, Ho H, Hoffman BB. Somatostatin inhibition of fructose-induced hypertension. Hypertension 1989; 14: 117–120.PubMedGoogle Scholar
  93. 93.
    Reaven GM. Are insulin resistance and/or compensatory hyperinsulinemia involved in the etiology and clinical course of patients with hypertension? Int J Obes 1995; 19: S2 - S5.Google Scholar
  94. 94.
    Zavaroni I, Mazza S, Dall’Aglio E, Gasparini P, Paseri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231: 235–240.PubMedGoogle Scholar
  95. 95.
    DeFronzo RA, Cooke C, Andres R, Faloona GR, David PJ. The effect of insulin in renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975; 55: 845–855.PubMedGoogle Scholar
  96. 96.
    Sharma AM, Schorr U, Distler A. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 1993; 21: 273–279.PubMedGoogle Scholar
  97. 97.
    Zavaroni I, Coruzzi P, Bonini L, Mossini GL, Musiari L, Gasparini P, Fantuzzi M, Reaven GM. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertension 1995; 8: 855–858.Google Scholar
  98. 98.
    Ferri C, Piccoli A, Laurenti O, Bettini C, DeMattia G, Santucci A, Balsono F. Atrial natriuretic factor in hypertensive and normotensive diabetic patients. Diabetes Care 1994; 17: 195–200.PubMedGoogle Scholar
  99. 99.
    Saad M, Lillioja S, Myomba BL, Castillo C, Ferraro R, De Gregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV, Bogardus C. Racial differences in the relation between blood pressure and insulin resistance. New Engl J Med 1991; 324: 733–739.PubMedGoogle Scholar
  100. 100.
    Falkner B, Hulman S, Tennenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension 1990; 16: 706–711.PubMedGoogle Scholar
  101. 101.
    Falkner B, Hulman S, Kushner H. Insulin-stimulated glucose utilization and borderline hypertension in young adult blacks. Hypertension 1993; 22: 18–25.PubMedGoogle Scholar
  102. 102.
    Anderson AE, Mark AL. The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 1993; 21: 136–141.PubMedGoogle Scholar
  103. 103.
    Hall JE, Brands MW, Kivlighn SD, Mizelle HL, Hildebrandt A, Gaillard CA. Chronic hyperinsulinemia and blood pressure. Hypertension 1990; 15: 519–527.PubMedGoogle Scholar
  104. 104.
    Brands MW, Hildebrandt DA, Mizelle HL, Halle JE. Sustained hyperinsulinemia increases arterial pressure in conscious rats. Am J Physiol 191; 260: R764 - R768.Google Scholar
  105. 105.
    Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Pt. 2: Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.PubMedGoogle Scholar
  106. 106.
    Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease and impaired glucose tolerance. the Whitehall Study. Lancet 1980; i: 1373–1376.Google Scholar
  107. 107.
    Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131–141.PubMedGoogle Scholar
  108. 108.
    Vaccaro O, Ruth KJ, Stamler J. Relationship of postload plasma glucose to mortality with 19-yr follow-up. Diabetes Care 1992; 13: 1328–1334.Google Scholar
  109. 109.
    Sheu WH-H, Jeng C-Y, Shieh S-M, Fuh MM-T, Shen DD-C, Chen Y-DI, Reaven GM. Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. Am J Hypertension 1992; 5: 444 448.Google Scholar
  110. 110.
    Shieh S-M, Shen M, Fuh MM-T, Chen Y-DI, Reaven GM. Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension. Atherosclerosis 1987; 67: 49–55.PubMedGoogle Scholar
  111. 111.
    MacMahon SW, Macdonald GJ, Blacket RB. Plasma lipoprotein levels in treated and untreated hypertensive men and women. Arteriosclerosis 1985; 5: 391–396.PubMedGoogle Scholar
  112. 112.
    Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1: 16–19.PubMedGoogle Scholar
  113. 113.
    Castelli WP, Garrison RJ, Wilson PWF, Abbott RO, Kalonsdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–2837.PubMedGoogle Scholar
  114. 114.
    Cambien F, Jaqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR. Is the level of serum triglyceride a significance predictor of coronary death in “normocholesterolic” subjects? The Paris Prospective Study. Am J Epidemiol 1986; 124: 624–632.PubMedGoogle Scholar
  115. 115.
    Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432–440.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Gerald M. Reaven

There are no affiliations available

Personalised recommendations